Monday, June 30, 2014
Evaluate Pharma reports that the market for prescription drugs, based on the consensus forecast for the leading 500 pharmaceutical and biotechnology companies, will grow by 5.1% per year (CAGR) to reach $1,017 bn. by 2020. Worldwide prescription growth was an uninspiring 0.3% in 2013, close to the 0.4% predicted in the previous edition of the World Preview report. This represents a return to modest growth versus the 1.6% contraction in 2012. The depreciation of the yen against the dollar has negatively impacted Japan's contribution to the worldwide market in 2013 by around $15bn. Sales at risk from patent expiries will average $3bn. per year to 2020; however, as an increasing proportion of sales are from biological products, the predicted erosion post-expiration is expected to be softer, thus protecting industry growth.
Worldwide Prescription Drug Sales in 2020: Top 20 Companies
1 Novartis 2 Roche 3 Sanofi 4 Pfizer 5 GlaxoSmithKline 6 Merck & Co.
7 Johnson & Johnson 8 AstraZeneca 9 Novo Nordisk 10 Gilead Sciences
11 AbbVie 12 Bayer 13 Bristol-Myers Squibb 14 Amgen 15 Takeda
16 Eli Lilly 17 Boehringer Ingelheim 18 Teva Pharmaceutical Industries
19 Astellas Pharma 20 Biogen Idec